Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure
Open Access
- 8 June 2016
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (4) , 974-982
Abstract
Aims: Urocortin 2 and urocortin 3 may play a role in the pathophysiology of heart failure and are emerging therapeutic targets. We aimed to examine the local and systemic cardiovascular effects of urocortin 2 and urocortin 3 in healthy subjects and patients with heart failure.Methods: Patients with heart failure (n = 8) and age and gender‐matched healthy subjects (n = 8) underwent bilateral forearm arterial blood flow measurement using forearm venous occlusion plethysmography during intra‐arterial infusions of urocortin 2 (3.6–36 pmol min−1), urocortin 3 (360–3600 pmol min−1) and substance P (2–8 pmol min−1). Heart failure patients (n = 9) and healthy subjects (n = 7) underwent non‐invasive impedance cardiography during incremental intravenous infusions of sodium nitroprusside (573–5730 pmol kg−1 min−1 ), urocortin 2 (36–360 pmol min−1 ), urocortin 3 (1.2–12 nmol min−1) and saline placebo.Results: Urocortin 2, urocortin 3 and substance P induced dose‐dependent forearm arterial vasodilatation in both groups (P < 0.05 for both) with no difference in magnitude of vasodilatation between patients and healthy subjects. During systemic intravenous infusions, urocortin 3 increased heart rate and cardiac index and reduced mean arterial pressure and peripheral vascular resistance index in both groups (P < 0.01 for all). Urocortin 2 produced similar responses to urocortin 3, although increases in cardiac index and heart rate were only significant in heart failure (P < 0.05) and healthy subjects (P < 0.001), respectively.Conclusion: Urocortins 2 and 3 cause vasodilatation, reduce peripheral vascular resistance and increase cardiac output in both health and disease. These data provide further evidence to suggest that urocortins 2 and 3 continue to hold promise for the treatment of heart failure.Keywords
This publication has 32 references indexed in Scilit:
- Vascular Effects of Urocortins 2 and 3 in Healthy VolunteersJournal of the American Heart Association, 2013
- Urocortins in heart failureBiochemical Pharmacology, 2010
- Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheepJournal of Endocrinology, 2009
- Urocortin 2 infusion in human heart failureEuropean Heart Journal, 2007
- Urocortin 2 Infusion in Healthy HumansJACC, 2007
- Integrated Hemodynamic, Hormonal, and Renal Actions of Urocortin 2 in Normal and Paced SheepCirculation, 2005
- In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanismsCanadian Journal of Physiology and Pharmacology, 2005
- CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilatorsBritish Journal of Pharmacology, 2004
- Intra‐arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerabilityBritish Journal of Clinical Pharmacology, 1997
- Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failureJACC, 1992